Education
About Us
Working with TipRanks
Follow Us
Salarius Pharmaceuticals (DE:FP1)
:FP1
FP1 Stock Chart & Stats
€3.48
--
Market closed
€3.48
--
Day’s Range― - ―
52-Week Range€0.34 - €56.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)91.00
Market Cap
€2.93M
Enterprise Value€1.11M
Total Cash (Recent Filing)€794.89K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.89
Shares OutstandingN/A
10 Day Avg. Volume65
30 Day Avg. Volume91
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Salarius Pharmaceuticals News
FP1 FAQ
What was Salarius Pharmaceuticals’s price range in the past 12 months?
Salarius Pharmaceuticals lowest stock price was €0.34 and its highest was €56.16 in the past 12 months.
What is Salarius Pharmaceuticals’s market cap?
Salarius Pharmaceuticals’s market cap is €2.93M.
When is Salarius Pharmaceuticals’s upcoming earnings report date?
Salarius Pharmaceuticals’s upcoming earnings report date is Mar 30, 2026 which is in 144 days.
How were Salarius Pharmaceuticals’s earnings last quarter?
Salarius Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported -€5.889 earnings per share for the quarter, missing the consensus estimate of N/A by -€5.889.
Is Salarius Pharmaceuticals overvalued?
According to Wall Street analysts Salarius Pharmaceuticals’s price is currently Overvalued.
Does Salarius Pharmaceuticals pay dividends?
Salarius Pharmaceuticals does not currently pay dividends.
What is Salarius Pharmaceuticals’s EPS estimate?
Salarius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Salarius Pharmaceuticals have?
Currently, no data Available
What happened to Salarius Pharmaceuticals’s price movement after its last earnings report?
Salarius Pharmaceuticals reported an EPS of -€5.889 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Salarius Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:FP1
Company Description
Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Options Prices
Currently, No data available
---